NC
FOLD

NinePointTwo Capital’s Amicus Therapeutics FOLD Stock Holding History

NinePointTwo Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,996
Closed -$251K – 273
2023
Q2 		$251K Hold
19,996
– – 0.1% 135
2023
Q1 		$221K Sell
19,996
-668
-3% -$8.23K 0.08% 191
2022
Q4 		$252K Buy
+20,664
New +$233K 0.1% 62

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NinePointTwo Capital's FOLD Position: Q3 2023 in Review

NinePointTwo Capital sold out of Amicus Therapeutics (FOLD) in Q3 2023, closing a stake of 19,996 shares — an estimated $251K sold.

NinePointTwo Capital first reported a position in FOLD in Q4 2022 and held it in 3 quarters. The position peaked at $252K in Q4 2022. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

  • NinePointTwo Capital reported no remaining Amicus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 19,996 Amicus Therapeutics shares in Q3 2023, an estimated $251K.
  • NinePointTwo Capital first reported a position in Amicus Therapeutics in Q4 2022 and held it in 3 quarters.
  • NinePointTwo Capital's Amicus Therapeutics position peaked at $252K in Q4 2022.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.